Viz.ai has launched the Viz Pulmonary Suite, an AI-powered platform designed to streamline the management of both acute and chronic pulmonary conditions within a single workflow. The suite focuses on three major areas—COPD, lung nodules and pulmonary embolism (PE)—with the goal of improving care coordination and ensuring clinically significant findings are acted on more consistently. By integrating directly into existing electronic health record systems, the platform aims to reduce the fragmentation that often occurs as patients move between imaging, emergency care and follow-up treatment.
The platform addresses a major challenge in pulmonary care: critical findings are frequently missed or not followed up appropriately. Research cited by Viz.ai shows that up to 71% of significant lung nodules do not receive proper follow-up, while most incidental pulmonary embolism cases are initially overlooked despite many being clinically important. The suite uses AI-driven workflows, automated guideline recommendations and real-time patient summaries to help clinicians identify high-risk patients earlier and coordinate care more effectively across the treatment continuum.
Viz.ai also highlighted measurable clinical and operational benefits tied to its pulmonary tools. In one study, the company’s PE workflow reduced time to treatment and lowered in-hospital mortality among high-risk patients. The platform is also intended to help health systems reduce referral leakage and improve patient retention by creating more connected care pathways. More broadly, the launch reflects growing use of AI to close gaps in care coordination, reduce administrative burden and support faster clinical decision-making in complex disease management.
Click here to read the original news story.
